Hainan Huluwa Pharmaceutical Group (605199.SH) announced that its wholly-owned subsidiary, Guangxi Weiwei Pharmaceutical Co., Ltd. (hereinafter referred to as...
Zhitong Finance and Economics APP News, Hainan Huluwa Pharmaceutical Group (605199.SH) announced that its wholly-owned subsidiary, Guangxi Weiwei Pharmaceutical Co., Ltd. (referred to as 'Guangxi Weiwei') recently received the "Drug GMP Compliance Inspection Result Notification" issued by the Guangxi Zhuang Autonomous Region Food and Drug Administration. The variety of products such as Yimucao Granules acquired by the company's Guangxi Wuzhou Sanjian Pharmaceutical Co., Ltd. (announcement number: 2023-004) passed the GMP compliance inspection after completing the shareholder change.
This GMP compliance inspection allowed Guangxi Weiwei to produce Weixueling Granules (National Medical License Z45022090), Yimucao Granules (National Medical License Z45021167), Dashanzha Granules (National Medical License Z45021365), Maian Granules (National Medical License Z45021162), Shilintong Granules (National Medical License Z45021164) at the production facilities located at 8 Fuxing Road, Laibin, Guangxi (pre-processing and extraction production line for traditional Chinese medicine); 10 Fangchenggang Road, Nanning (granule production line), and Chujipi (National Medical License Z20070010) at the address above; in the production facilities located at 8 Fuxing Road, Laibin, Guangxi (pre-processing and extraction production line for traditional Chinese medicine); 10 Fangchenggang Road, Nanning (tablet production line); and at the production facilities located at 10 Fangchenggang Road, Nanning (tablet production line) to produce pediatric aspirin tablets (National Medical License H45021008) and pediatric aspirin diphenhydramine tablets (National Medical License H45021007).
